Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Damoctocog alfa pegol - Bayer HealthCare Pharmaceuticals

Next Previous
Drug Profile

Damoctocog alfa pegol - Bayer HealthCare Pharmaceuticals

Alternative Names: Antihemophilic factor [recombinant] PEGylated-aucl; BAY-949027; Damoctocog alfa pegol; Jivi; peg rFVIII; PEG rFVIII mutein; PEGylated B-Domain-Delted Recombinant rFVIII; PEGylated BDD-rFVIII; rFVIII glycopegylated

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Amides; Amines; Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Propionic acids; Pyrrolidines; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A
  • Registered Haemorrhage

Most Recent Events

  • 27 Mar 2023 Registered for Haemophilia A (In adolescents, In children, In adults, Treatment-experienced) in Australia (IV)
  • 23 Mar 2022 Bayer initiates a phase III trial for Haemophilia A (Treatment-experienced, In children) in Canada (IV,Infusion) (NCT05147662) (EudraCT2021-004858-30)
  • 07 Dec 2021 Bayer HealthCare Pharmaceuticals plans a phase III trial for Haemophilia A (Treatment-experienced, In children) in Canada (IV,Infusion), (NCT05147662) (EudraCT2021-004858-30)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top